Comprehensive clinical staging for resectable lung cancer: Clinicopathological correlations and the role of brain MRI

Journal of Thoracic Oncology

Volumn 11, Issue 11, 2016, Pages 1970-1975

  Vernon, Jordyn ^a   Andruszkiewicz, Nicole ^b   Schneider, Laura ^a   Schieman, Colin ^a   Finley, Christian J ^a   Shargall, Yaron ^a   Fahim, Christine ^a   Farrokhyar, Forough ^b   Hanna, Waël C ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Lung cancer staging; Lung cancer surgery; MRI; NSCLC

Indexed keywords

ABDOMEN; AGED; ARTICLE; BRAIN METASTASIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; ENDOBRONCHIAL ULTRASONOGRAPHY; FEMALE; FOLLOW UP; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIASTINOSCOPY; NEUROIMAGING; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THORAX; WHOLE BODY CT; WHOLE BODY PET; BRAIN; DIAGNOSTIC IMAGING; LUNG NEOPLASMS; PATHOLOGY; PROCEDURES;

AGED; BRAIN; FEMALE; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM STAGING; RETROSPECTIVE STUDIES;

EID: 84995904493     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.06.003     Document Type: Article

References (30)

1. Ettinger DS, Wood DE, Akerley W, et al. NCCN clinical practice guidelines in oncology: non-small cell lung cancer version 1.2016. Oct 23, 2015. https://www.nccn. org/professionals/physician-gls/pdf/nscl.pdf. Accessed Nov 8, 2015.
2. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer. Chest. 2013;143: e211S-e250S.
3. Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;00:1-13.
4. De Wever W, Verschakelen J, Coolen J. Role of imaging in diagnosis, staging and follow-up of lung cancer. Curr Opin Pulm Med. 2014;20:385-392.
5. Kent MS, Port JL, Altorki NK. Current state of imaging for lung cancer staging. Thorac Surg Clin. 2004;14:1-13.
6. Sihoe ADL, Yim APC. Lung cancer staging. J Surg Res. 2004;117:92-106.
7. Loutfi S, Khankan A, Al Ghanim S. Guidelines for multi-modality radiological staging of lung cancer. J Infect Public Health. 2012;5:S14-S21.
8. Ettinger DS, Akerley W, Bepler G, et al. NCCN Clinical Practice Guidelines in Oncology on Non-Small Cell Lung Cancer. J Natl Compr Canc Netw. 2010;8:740-801.
9. Tsim S, O'Dowd CA, Milroy R, et al. Staging of non-small cell lung cancer (NSCLC): a review. Respir Med. 2010;104:1767-1774.
10. Paul NS, Ley S, Metser U. Optimal imaging protocols for lung cancer staging: CT, PET, MR imaging, and the role of imaging. Radiol Clin N Am. 2012;50:935-949.
11. Brocken P, van der Heijden HFM, Dekhuijzen PNR, et al. High performance of F-fluorodeoxyglucose positron emission tomography and contrast-enhanced CT in a rapid outpatient diagnostic program for patients with suspected lung cancer. Respiration. 2014;87: 32-37.
12. Ung YC, Maziak DE, Vanderveen JA, et al. 18Fluo-rodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst. 2007;99:1753-1767.
13. Kligerman S. The clinical staging of lung cancer through imaging: a radiologist's guide to the revised staging system and rationale for the changes. Radiol Clin N Am. 2014;52:69-83.
14. Kim MP, Correa AM, Hofstetter W, et al. Limitations of 18F-2-deoxy-D-glucose positron emission tomography in N1 detection in patients with pathologic stage II-N1 and implications for management. Ann Thorac Surg. 2015;99:414-420.
15. Kim SY, Kim JS, Park HS, et al. Screening of brain metastasis with limited magnetic resonance imaging (MRI): clinical implications of using limited brain MRI during initial staging for non-small cell lung cancer patients. J Korean Med Sci. 2005;20:121-126.
16. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471-1474.
17. Na II, Lee TH, Choe DH, et al. A diagnostic model to detect silent brain metastases in patients with non-small cell lung cancer. Eur J Cancer. 2008;44:2411-2417.
18. Earnest F, Riu JH, Miller GM, et al. Suspected non-small cell lung cancer: incidence of occult brain and skeletal metastases and effectiveness of imaging for detection-pilot study. Radiology. 1999;211:137-145.
19. Jena A, Taneja S, Talwar V, et al. Magnetic resonance (MR) patterns of brain metastasis in lung cancer pa-tients: correlation of imaging findings with symptom. J Thorac Oncol. 2008;3:140-144.
20. Hubbs JL, Boyd JA, Hollis D, et al. Factors associated with the development of brain metastases. Cancer. 2010;116:5038-5046.
21. Nelson JS, Allen LD, Parker LA, et al. Early brain recurrences are potentially detectable in asymptomatic, early stage lung adenocarcinoma. Oncol Lett. 2011;23: 716-721.
22. Park HY, Kim YH, Kim H, et al. Routine screening by brain magnetic resonance imaging decreased the brain metastasis rate following surgery for lung adenocarci-noma. Lung Cancer. 2007;58:68-72.
23. O'Dowd EL, Kumaran M, Anwar S, et al. Brain metastases following radical surgical treatment of non-small cell lung cancer: is preoperative brain imaging important? Lung Cancer. 2014;86:185-189.
24. Baldwin DR, White B, Schmidt-Hansen M, et al. Diagnosis and treatment of lung cancer: summary of updated NICE guidance. Br Med J. 2011;342:d2110.
25. Lim E, Baldwin D, Beckles M, et al. Guidelines on the radical management of patients with lung cancer. Thorax. 2010;65:1-27.
26. Backhus LM, Farjah F, Varghese TK, et al. Appropriateness of imaging for lung cancer staging in a national cohort. J Clin Oncol. 2014;32:3428-3435.
27. Yohena T, Yoshino I, Kitajima M, et al. Necessity of preoperative screening for brain metastasis in non-small cell lung cancer patients without lymph node metastasis. Ann Thorac Cardiovasc Surg. 2004;10: 347-349.
28. Silvestri GA, Tanoue LT, Margolis ML, et al. The nonin-vasive staging of non-small cell lung cancer: the guidelines. Chest. 2003;123:147S-156S.
29. Choosing Wisely. The Society of Thoracic Surgeons. Patients with suspected or biopsy proven stage I NSCLC do not require brain imaging prior to definitive care in the absence of neurologic symptoms. http://www. choosingwisely.org/clinician-lists/society-thoracic-surgeons-brian-imaging-for-patients-with-suspected-or-biopsy-proven-stage-i-nsclc/. Accessed Nov 15, 2015.
30. Balekian AA, Fisher JM, Gould MK. Brain imaging for staging of patients with clinical stage IA non-small cell lung cancer in the National Lung Screening Trial: adherence with recommendations from the Choosing Wisely campaign. Chest. 2015;149: 943-950.